This inventor holds 1 USPTO granted patent. Top assignee: The State University of New York. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Innovations in Colorectal Cancer Treatment by Haiyan Zhai
Introduction
Haiyan Zhai is an accomplished inventor based in Holtsville, NY (US). He has made significant contributions to the field of cancer research, particularly in the identification of biomarkers for colorectal cancer. His work focuses on the therapeutic potential of microRNA-129 in cancer treatment.
Latest Patents
Haiyan Zhai holds a patent for "MicroRNA-129 as a biomarker for colorectal cancer." This patent describes methods for identifying subjects who would benefit from treatment with chemotherapeutic agents. The disclosure is based on the observation that miR-129 expression levels are reduced in colorectal cancer. The patent provides therapeutic compositions and methods for altering the expression of a miR-129 effector. It also outlines methods for characterizing the stage of colorectal cancer based on miR-129 expression levels. Furthermore, it identifies miR-129 as a predictive biomarker for cancer diagnosis and treatment with directed therapeutic agents, including miR-129 nucleic acid molecules and chemotherapeutic agents. The patent also highlights novel therapeutic agents that modulate the levels of BCL2, TS, and E2F3 expression, which can sensitize subjects to chemotherapeutic treatments.
Career Highlights
Haiyan Zhai is affiliated with the State University of New York, where he continues to advance research in cancer therapeutics. His innovative approach to utilizing microRNA as a biomarker has the potential to transform treatment protocols for colorectal cancer patients.
Collaborations
Some of his notable coworkers include Mihriban Karaayvaz and Jingfang Ju, who contribute to the collaborative research efforts in the field of cancer treatment.
Conclusion
Haiyan Zhai's work in identifying microRNA-129 as a biomarker for colorectal cancer represents a significant advancement in cancer research. His contributions have the potential to improve diagnostic and therapeutic strategies for patients suffering from this disease.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile